Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms. - Wikidata - wikimedia - TriplyDB

Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms.

Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms.

http://www.wikidata.org/entity/Q37637905

about

MicroRNA-107-5p suppresses non-small cell lung cancer by directly targeting oncogene epidermal growth factor receptor.

P2860

Q41343483-A8AB1D32-04B0-4D20-A450-152335F558DD

P2860

Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms.

http://www.wikidata.org/entity/Q37637905

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 February 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Second-Line Treatment of NSCLC ...... n Times of Shifting Paradigms.

@en

Second-Line Treatment of NSCLC ...... n Times of Shifting Paradigms.

@nl

type

label

Second-Line Treatment of NSCLC ...... n Times of Shifting Paradigms.

@en

Second-Line Treatment of NSCLC ...... n Times of Shifting Paradigms.

@nl

prefLabel

Second-Line Treatment of NSCLC ...... n Times of Shifting Paradigms.

@en

Second-Line Treatment of NSCLC ...... n Times of Shifting Paradigms.

@nl

P1433

Q37637905-77EB4613-0218-4ED3-B1DB-A9AC384111F4

P1476

Q37637905-BFAF668E-4005-40AF-BB5E-4B9BDD74D051

P2093

Q37637905-9F9AD30C-A565-4BCE-9198-4D2E703D3512

P2860

Q37637905-029F3F04-0B6F-44F6-8A79-FF0D623FF946

Q37637905-030E6932-CB17-4DBA-B5EE-94ACB64F42BB

Q37637905-042AF1C1-9656-46DE-B0E6-E8106D4F4B52

Q37637905-098909F4-1559-4DF3-BA8D-CC8C813640A8

Q37637905-09CC5E15-0FB1-42D4-A4F3-95F307F38AE4

Q37637905-0D879D49-6756-46EA-93E5-CF5AC3D8B396

Q37637905-146B341E-6DCC-47D0-8E43-03B6EB2FAA0C

Q37637905-1699BE9F-A365-46CC-BCA8-BFE5EBB20DB5

Q37637905-1976E0FE-39AD-4226-9B97-FBAD42DABB69

Q37637905-19B9CB1D-BD22-4ADA-99E3-4563A3BF8236

P304

Q37637905-9F09E3F4-CACC-4013-A97B-A7D8AAF450E6

P31

Q37637905-46F48EC7-CD6A-4DC7-806C-F666C0E73AB0

P356

Q37637905-BE1BEDCE-B83C-491F-8E6A-9358D6C7D12C

P478

Q37637905-63A2BB44-02FB-4698-8EDF-459B552C3819

P577

Q37637905-5C230FDF-EC8C-4AB9-9B32-0BC9437F7537

P698

Q37637905-A69BC200-5C6D-4D91-BDA6-B8EA12C5F933

P932

Q37637905-AA82FE0E-CC1E-4979-80B1-9C065025876F

P356

FMED.2017.00009

P1433

Frontiers in medicine

P1476

Second-Line Treatment of NSCLC ...... n Times of Shifting Paradigms.

@en

P2093

Jens Köhler

http://www.w3.org/2001/XMLSchema#string

P2860

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Comprehensive genomic characterization of squamous cell lung cancers.

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Erlotinib in previously treated non-small-cell lung cancer

P304

9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FMED.2017.00009

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28243590

http://www.w3.org/2001/XMLSchema#string

P932

5303897

http://www.w3.org/2001/XMLSchema#string